Thermo Fisher Scientific Gibco CTS Rotea Counterflow Centrifugation System

Thermo Fisher Scientific announced its Gibco CTS Rotea Counterflow Centrifugation System — a modular, closed cell therapy processing system that enables scalable cell therapy development and manufacturing. The system facilitates workflows from research through to GMP clinical development and commercial manufacturing.

Few cell therapies in development become commercially available due to several factors: safety and efficacy requirements; difficulties in transferring research protocols to manufacturing processes; lack of scalability of these therapies; high cost of facilities, labour and equipment; and complexity of the processes involved. Using a modular, closed system for cell processing enables time-consuming processes to be decoupled from rapid processes, improving facility and equipment utilisation and reducing the capital investment required. Use of the same system from research through process development and commercial manufacturing lowers the risk of process delays associated with changing systems. Sterile, closed, single-use kits enable cell processing in grade C cleanrooms, leading to transfer and scale-out of processes.

The multifunctional and highly flexible CTS Rotea system can easily integrate into existing workflows, process low- to mid-range input volumes and deliver low output volumes. Consisting of an instrument, a closed sterile single-use kit and user-programmable software, the system provides processing flexibility to support a broad range of protocols for cell separation, washing and concentration with a cell recovery yield of greater than 95% while maintaining cell viability. It should therefore help researchers overcome manufacturing hurdles and bring the potential of cell therapies to more patients.